Financing channel feed – Endpoints News

Financing channel feed

RA Capital jumps into the melee on TTR amyloidosis, backing a $91M development plan for a BridgeBio drug

8 years ago

On the heels of major Pfizer deal, Arvinas snags $55M Series C for protein degradation cancer programs

8 years ago

With $340M crossover fund, Sofinnova Partners pivots to late-stage biotech investments while maintaining European focus

8 years ago

Belldegrun teams with a group of top VC players to unveil a $295M biotech fund at Vida Ventures

8 years ago

Arie Belldegrun raises $300M, grabs Pfizer’s allogeneic CAR-T portfolio and launches a groundbreaking drive to commercialization

8 years ago

Backed by giants, antibiotics upstart Macrolide gets $20M and an ex-Novartis exec as CEO

8 years ago

Unum Therapeutics stumbles on its Nasdaq debut, raising $69M and some transparency issues

8 years ago

Versant-backed Tempest grabs a $70M round with plans to drive a slate of I/O drugs into the clinic

8 years ago

Works in mice? It’s a winner for Homology as IPO reaps $144M haul, with biotech on a roll

8 years ago

Chinese oncology startup Adagene closes $50M Series C led by Sequoia Capital

8 years ago

Singapore’s Aslan Pharma lines up an $86M IPO to fund pivotal cancer drug studies

8 years ago

Shanghai drugmaker Hua hauls in $117M megaround, with plans for hefty Hong Kong IPO

8 years ago

With major funding from Novartis, Surface Oncology launches a CD47 trial amid a swarm of rivals and files for $75M IPO

8 years ago

Backed in part by Roche, Denmark's NMD gets $47M to run orphan neuromuscular disease trials

8 years ago

MorphoSys files for $150M IPO to fuel its hopeful DLBCL drug launch

8 years ago

Another immunometabolism deal? Johns Hopkins spinout Dracen lands $36M investment from Deerfield

8 years ago

Third Rock debuts immunometabolism startup Rheos with $60M launch round

8 years ago

Another mega-startup: China investors back TCR2's $125M cash round to fuel a preclinical assault on solid tumors

8 years ago

Trendy anti-aging biotech Unity adds $55M as it preps first human trial to flush senescent cells

8 years ago

Alzheon files for $80M IPO to take once-failed Alzheimer's drug into PhIII

8 years ago

CRISPR pioneer Feng Zhang co-founds a 'limitless' biotech upstart with big plans for speeding new drug development

8 years ago

Hinting at an IPO and big things ahead for synthetic lethality, preclinical Ideaya touts a $94M round

8 years ago

The biotech IPO party rocks on with $120M raise for I/O player Arcus Biosciences

8 years ago

Endocrine experts at Crinetics bag $63.5M to push R&D on an experimental pill for acromegaly

8 years ago

First page Previous page 131 132 133134135 136 137 Next page Last page